Cargando…

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly

CONTEXT: In active acromegaly, the lipolytic and insulin antagonistic effects of growth hormone (GH) excess alter adipose tissue (AT) deposition, reduce body fat, and increase insulin resistance. This pattern reverses with surgical therapy. Pegvisomant treats acromegaly by blocking GH receptor (GHR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuker, Adriana P, Shen, Wei, Jin, Zhezhen, Singh, Simran, Chen, Jun, Bruce, Jeffrey N, Freda, Pamela U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853172/ https://www.ncbi.nlm.nih.gov/pubmed/33553983 http://dx.doi.org/10.1210/jendso/bvab004

Ejemplares similares

Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2023)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
por: Kuhn, Emmanuelle, et al.
Publicado: (2015)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

SAT-438 Visceral and Marrow Adiposity in Patients with Acromegaly; Relationships to Disease Activity, Markers of Bone Turnover, Bone Mineral Density, and Peripheral Bone Microarchitecture
por: Kuker, Adriana, et al.
Publicado: (2019)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

Persistent Deficits in Bone Quality in Treated Acromegaly: Evidence From Assessments of Microstructure
por: Kuker, Adriana P, et al.
Publicado: (2023)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

The acromegaly lipodystrophy
por: Freda, Pamela U.
Publicado: (2022)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
por: Moore, David J, et al.
Publicado: (2009)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

MON-307 Prospective, Longitudinal Study of Glucose-Suppressed GH Levels in 87 Acromegaly Patients with IGF-1 Normalization After Surgical Therapy: Prognostic Value of Nadir GH Levels for Long-Term Remission or Recurrence
por: Freda, Pamela, et al.
Publicado: (2020)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
por: Burren, Christine P, et al.
Publicado: (2023)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series
por: Rochira, Vincenzo, et al.
Publicado: (2012)

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
por: Pirchio, R., et al.
Publicado: (2023)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Changes in Quality of Life After Long-Term Biochemical Control of Acromegaly
por: Kimball, Allison, et al.
Publicado: (2021)

Neuromuscular Blockade Correlates with Hormones and Body Composition in Acromegaly
por: Zhang, Yu, et al.
Publicado: (2020)

Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study
por: Freda, Pamela U, et al.
Publicado: (2020)

Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation
por: Mallea-Gil, Maria Susana, et al.
Publicado: (2016)

Long-Term Effects of Placental Growth on Overweight and Body Composition
por: Eriksson, Johan G., et al.
Publicado: (2012)

Lipodystrophy during pegvisomant therapy: a case report and review of the literature
por: Buyuktas, D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oeu7b1jgociqbqmj2sd0256eju